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GM cropNew biotechnology-derived crop traits have been developed utilizing the natural process of RNA interfer-
ence (RNAi). However, plant-produced double stranded RNAs (dsRNAs) are not known to present a haz-
ard to mammals because numerous biological barriers limit uptake and potential for activity. To evaluate
this experimentally, dsRNA sequences matching the mouse vATPase gene (an established target for con-
trol of corn rootworms) were evaluated in a 28-day toxicity study with mice. Test groups were orally
gavaged with escalating doses of either a pool of four 21-mer vATPase small interfering RNAs (siRNAs)
or a 218-base pair vATPase dsRNA. There were no treatment-related effects on body weight, food con-
sumption, clinical observations, clinical chemistry, hematology, gross pathology, or histopathology end-
points. The highest dose levels tested were considered to be the no observed adverse effect levels
(NOAELs) for the 21-mer siRNAs (48 mg/kg/day) and the 218 bp dsRNA (64 mg/kg/day). As an additional
exploratory endpoint, vATPase gene expression, was evaluated in selected gastrointestinal tract and sys-
temic tissues. The results of this assay did not indicate treatment-related suppression of vATPase. The
results of this study indicate that orally ingested dsRNAs, even those targeting a gene in the test species,
do not produce adverse health effects in mammals.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
RNA from plants and animals is present in all food and feed
products, including RNAs involved in RNA interference (RNAi) and
other mechanisms of RNA-mediated gene regulation (Heisel et al.,
2008; Ivashuta et al., 2009; Jensen et al., 2013; Parrott et al.,
2010; Petrick et al., 2013). RNA-mediated gene regulation is the
basis for some phenotypes selected through conventional breeding
(Della Vedova et al., 2005; Tuteja et al., 2004), has been utilized in
several commercially approved biotechnology-derived crops (e.g.,
virus resistant and nutritionally enhanced crops; (Frizzi and
Huang, 2010; Parrott et al., 2010), and continues to hold promise
as a selective set of tools for producing new traits in biotechnol-
ogy-derived crops. Through expression of noncoding RNA mole-
cules, new traits can be conferred to a biotechnology-derived crop
(e.g., quality traits, insect protection). Noncoding RNAs introducedinto plants can be small interfering RNAs (siRNAs), which are RNA
duplexes of approximately 21–25 base pairs (Siomi and Siomi,
2009), or longer double stranded RNA precursors (e.g., 200–400
base pairs). Naturally-occurring double stranded nucleic acids,
including noncoding RNAs, are present in all plant- and animal-
based foods and thus, there is a history of safe consumption of small
RNAs with 100% identity to human genes (Ivashuta et al., 2009) and
longer double stranded RNAs (dsRNAs) encoding small RNAs having
100% identity to human genes (Jensen et al., 2013). The history of
safe consumption of dietary RNAs also includes long dsRNAs con-
tained in plants infected with RNA-containing viruses (Fukuhara
et al., 2006; Gould and Francki, 1981).
Extensive physical and biochemical barriers exist in vertebrates,
including mammals and humans, that limit the potential for both
oral uptake and oral activity of both natural and therapeutic dsR-
NAs (reviewed in (Juliano et al., 2009; O’Neill et al., 2011; Petrick
et al., 2013). Key components of this barrier system include nuc-
leases in the gastrointestinal tract (including nucleases from saliva)
and acidic conditions of the stomach. Multiple cellular membrane
barriers must also be crossed for an ingested RNA to get from the
lumen of the intestine into the blood and into cells of distal organs
to act systemically, a formidable challenge for these large polar
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2004; Petrick et al., 2013). As demonstrated for small therapeutic
dsRNAs (e.g., siRNAs and miRNAs), any dsRNAs that are able to pass
through these barriers are likely to be sequestered in endosomal/
lysosomal vesicles and become degraded by nucleases (Forbes
and Peppas, 2012; Gilmore et al., 2004).
The aforementioned barriers have posed a major challenge for
systemic delivery of oligonucleotide therapeutics and remain a
key limitation in their clinical development (Behlke, 2006;
Nguyen et al., 2008; O’Neill et al., 2011; Vaishnaw et al., 2010). Oral
oligonucleotide therapeutics will continue to face signiﬁcant efﬁ-
cacy hurdles due to their low oral bioavailability. For example, an
unformulated, but chemically stabilized DNA oligonucleotide,
exhibited very low oral bioavailability of around 0.3% (Nicklin
et al., 1998). Oligonucleotides formulated in delivery agents
intended to enhance oral delivery also have limited oral bioavail-
ability in the range of about 1–10% (Raoof et al., 2004; Tillman
et al., 2008). Thus, systemic delivery of oligonucleotide therapeu-
tics, including dsRNAs, typically employs high doses of stabilized
oligonucleotides formulated in specialized delivery agents
(Behlke, 2006). Nucleic acids in the blood are subjected to nucleas-
es (Houck, 1958) and rapid ﬁltration and elimination by the kid-
neys (Molitoris et al., 2009; Vaishnaw et al., 2010). Chemically
stabilized siRNA oligonucleotides administered through intrave-
nous injection (a route which bypasses gastrointestinal barriers)
exhibited a half-life of less than ten minutes and extensive degra-
dation into shorter sequences or individual nucleosides, RNA
sequences not long enough for initiation of RNAi (Christensen
et al., 2013). Furthermore, intravenous administration of a stabi-
lized therapeutic siRNA at doses up to 200 mg/kg was considered
safe in rats (Thompson et al., 2012), most likely due to rapid
metabolism and clearance. Therefore, there is a strong weight of
scientiﬁc evidence from studies conducted with stabilized dsRNA
molecules that provides support for the conclusion that orally
ingested naked/unstabilized dsRNAs from biotechnology-derived
crops would have limited systemic uptake after oral administra-
tion and, if absorbed, would undergo rapid metabolism and clear-
ance (thereby limiting biodistribution), resulting in a very low
potential for oral toxicity.
Orally ingested dsRNA has not been observed to undergo appre-
ciable uptake in mammals, as demonstrated by several studies
evaluating levels of mature, plant-derived miRNAs (Dickinson
et al., 2013; Snow et al., 2013; Witwer et al., 2013). These studies
measured potential for functional miRNA uptake rather than total
exogenous dsRNA uptake, as mature miRNAs (measured by stem-
loop primer based qPCR assays) would be associated with the RNAi
machinery in vivo (Yates et al., 2013). Nevertheless, these data rep-
resent a surrogate for evaluating functional uptake of exogenous
dsRNAs. Ingested RNAs are not known to be toxic to mammals,
acutely or otherwise, most likely owing to limited uptake, rapid
clearance, and extensive degradation as described above. The con-
cept of limited potential for oral toxicity or activity of ingested dsR-
NAs was experimentally tested in a 28-day repeat oral dose
toxicity evaluation conducted at high doses relative to anticipated
dietary exposures. The siRNAs and the long dsRNA selected for use
in this toxicity evaluation were selected to have 100% sequence
identity with the mouse ortholog of vacuolar ATPase. This gene tar-
get was selected because it provides insecticidal activity against
corn rootworms when expressed in corn plants (Baum et al., 2007).
Vacuolar ATPase is an ATP-dependent proton pump involved
with acidiﬁcation of cellular organelles involved with membrane
trafﬁcking processes (Jefferies et al., 2008). As reviewed by Jeffries
and colleagues, these organelles include endosomes and lysosomes
necessary for protein catabolism and for release and degradation of
receptor ligands during receptor internalization/recycling. The
dsRNAs utilized in this study represent a reasonable worst-casescenario for evaluating the oral safety of dsRNAs in the test species,
use of a target sequence that controls insects and has 100%
sequence identity to the consuming organism. The results pre-
sented herein can be used to support the weight of the evidence
in the scientiﬁc literature regarding the history of safe consump-
tion of both small and long dsRNAs and the effectiveness of biolog-
ical barriers to limit the potential for activity of ingested dsRNAs,
thus providing further evidence for the established safety of
ingested RNA.2. Materials and methods
2.1. Oral toxicology evaluation in mice
A 28-day repeat dose oral toxicity study (adapted from OECD
Test Guideline 407) was conducted in CD-1 mice with RNA test
materials described below (Section 2.2). Although the rat is the
preferred rodent species for this OECD guideline, mice were
selected as the test species due to test substance limitations. This
study was conducted according to the United States Environmental
Protection Agency Good Laboratory Practices (GLP). Animals were
individually housed and were provided free access to tap water
and Purina Mills Certiﬁed Rodent Diet 5002 in ‘‘meal’’ form. The
average daily temperatures and relative humidity in the study
room ranged from 18 to 26 C and 30% to 70%, respectively, and
the room had a 12 h light/dark daily photoperiod.
Upon receipt, animals were acclimated for approximately
1 week prior to initiation of dosing. Animals were matched by
weight with males weighing 22.7–34.0 g (about 7 weeks of age)
and females weighing 25.1–30.6 g (13 weeks of age) at initiation.
Dose groups consisted of 8 mice per sex. Eight animals per group
(rather than the guideline speciﬁed ﬁve mice per group) were
selected to maximize the number of animals per group from which
both hematology and clinical chemistry data could be secured due
to small blood volume and to enhance the reliability of gene
expression measurements. Control groups were given vehicle con-
trol (nuclease-free water; Group 1) or a RNA negative control (RNA
from torula yeast; has a history of safe use in food; 100 mg/kg dose,
not corrected for purity; Group 2). Test groups were administered
either a 218-bp vATPase dsRNA (analytically conﬁrmed dose levels
of 0.64, 6.4, and 64 mg/kg/day; Groups 3–5, respectively) or a pool
of four 21-mer vATPase siRNAs (analytically conﬁrmed dose levels
of 0.45, 4.9, and 48 mg/kg/day; Groups 6–8, respectively) once
daily by oral gavage for a minimum of 28 consecutive days. Study
endpoints consisted of daily clinical observations, daily mortality
and moribundity checks, weekly body weights (unfasted; day 28
body weights taken on animals fasted overnight with free access
to water), weekly food consumption, as well as serum chemistry,
hematology, gross pathology, organ weights, and microscopic
pathology (in both control groups and the high dose groups for
both test substances) at the end of the dosing period. Details of
parameters evaluated and methods utilized for data collection
are presented in the Supplemental Section under Supplemental
methods.
Although gene expression is not considered a standard toxico-
logical endpoint and is not routinely conducted nor required by
OECD Test Guideline 407, an exploratory vATPase gene expression
analysis was conducted on selected tissues in this study (stomach,
duodenum, ileum, liver, kidney, spleen, brain, and humerus). This
endpoint was added to further explore whether ingested RNA
can modulate gene expression in mammals.
An additional 28-day in vivo assessment was conducted as a fol-
low-up to evaluate reproducibility of stomach gene expression
ﬁndings and white blood cell count differences observed in the ini-
tial study and was conducted according to similar design principles
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weighing 23.1–27.8 g and approximately 11 weeks old at initia-
tion. Eight female mice per group were administered either nucle-
ase-free water or the 218-bp dsRNA at a dose level of 65 mg/kg/day
(analytically conﬁrmed). Endpoints consisted of clinical observa-
tions, mortality and moribundity checks, body weights, food con-
sumption, hematology, gross pathology, organ weights, and the
exploratory vATPase gene expression analysis in the stomach.
These data points were collected using the same methods as uti-
lized in the initial 28-day toxicology study and are described in
the Supplemental Section. Given the lack of any impact on animal
health/mortality and an absence of ﬁndings in clinical observa-
tions, body weights, food consumption, hematology, gross pathol-
ogy, or organ weights in this second study, only the gene
expression and white blood cell count data are presented herein.
2.2. Test materials
RNA test materials included an unmodiﬁed 218-base pair dou-
ble-stranded RNA (Monsanto Company, Creve Coeur, MO) or a pool
of four 21-mer siRNA duplexes (Dharmacon, Waltham, MA) pooled
together in equal concentrations. These RNAs were formulated as
solutions in nuclease free water (Ambion, Carlsbad, CA). The siRNA
duplex solutions were prepared fresh daily. All RNAs were
designed to target the mouse ortholog of vacuolar ATPase (vAT-
Pase; NM_007508) The RNA negative control used in the study
was torula yeast RNA (Sigma Aldrich #R6625), formulated in
0.1 M acetate buffer, pH 5.0 to ensure solubility (insoluble in nucle-
ase free water). Stability and concentration were analytically con-
ﬁrmed to be within 10% of target by Monsanto Company under GLP
conditions using an HPLC method employing UV detection. Dose
levels are reported as the mean analytically conﬁrmed RNA con-
centration across all study weeks by treatment group.
The 218-bp dsRNA was designed using the BLASTALL computer
algorithm (Gish and States, 1993) through the National Center for
Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov)
to identify the mouse ortholog of corn rootworm vATPase. The
BlastN (Gish and States, 1993) and BlastX (Altschul et al., 1990;
Gish and States, 1993) tools were used in the design. BlastN
statistically determines the most accurate nucleotide alignment
and BlastX determines the most likely protein sequence. The
BLASTALL algorithm (Gish and States, 1993) was used to match
the corn root worm vATPase sequence to NCBI’s standard non-
redundant nucleotide database with default parameters (allowing
for mismatches). The sequence with maximum percent identity
(81%) as well as highest match length (161 nt) with the mouse
vATPase was selected and extended in both directions to cover
the sequence orthologous to the corn rootworm targeting vATPase
sequence (Baum et al., 2007). The sequence identiﬁed was the
sense strand. A 218-bp subset of this sequence was generated
by Monsanto. The identity of this sequence was conﬁrmed by
Northern blot.
The four siRNAs used were identiﬁed in silico as the putative
siRNA sequences most likely to be active within the 218-bp region
using proprietary siRNA design algorithms from Dharmacon
(http://www.thermoscientiﬁcbio.com/Dharmacon/). These siRNA
duplexes were synthesized by Dharmacon (Lafayette, CO) to
include 20 O-methyl residues on the 30 ends (indicated by a lower
case ‘‘m’’ prior to the base abbreviation in sequences below), as this
modiﬁcation is incorporated in plant produced siRNAs and miRNAs
through the activity of HEN-1 methylase (Li et al., 2005).
The sequences of the RNAs were as follows:
siRNA Duplex 1: Sense strand: 50 GGA CCA AAG CUA AGG AGA
UCmC 30 Antisense stand: 30 mCUC CUG GUU UCG AUU CCU
CUA 50siRNA Duplex 3: Sense strand: 50 UCG UGC AGC UCG UGG GAA
AGmG 30 Antisense stand: 30 mUUA GCA CGU CGA GCA CCC
UUU 50
siRNA Duplex 5: Sense strand: 50 UCA ACU GGC UCA UCA GCU
ACmA 30 Antisense stand: 30 mACA GUU GAC CGA GUA GUC
GAU 50
siRNA Duplex 7: Sense strand: 50 UGG ACG AGU ACU AUG ACA
AGmC 30 Antisense stand: 30 mGGA CCU GCU CAU GAU ACU
GUU 50
218-bp dsRNA (Sense strand): 50 GCU CAG CGC AAG CAC UUC
CCC UCU GUC AAC UGG CUC AUC AGC UAC AGC AAG UAC
AUG CGU GCC CUG GAC GAG UAC UAU GAC AAG CAC UUC
ACG GAG UUU GUU CCU CUG AGG ACC AAA GCU AAG GAG
AUC CUG CAG GAA GAA GAG GAU CUG GCA GAA AUC GUG
CAG CUC GUG GGA AAG GCC UCU UUA GCA GAG ACG GAU
AAA AUC ACU CUG GAG GUA GC 30
2.2.1. Efﬁcacy of test materials
The ability of the 21-mer siRNAs to suppress the mouse vATPase
target gene was conﬁrmed in vitro through transfection of each siR-
NA duplex into mouse kidney cells (line ATCC# CCL-139) (Fig. 1).
Cells were cultured in Eagle’s Minimum Essential Medium (EMEM)
growth media supplemented with 10% fetal bovine serum and
were cultured at 37 C under 5% CO2. Cells were transfected using
Lipofectamine2000 (Life Technologies, Grand Island, NY) per the
manufacturer’s speciﬁcations. Efﬁcacy was conﬁrmed 24 h after
transfection using qPCR as described below (Section 2.3) and
knockdown was conﬁrmed in the absence of any apparent cytotox-
icity as determined using the Roche Cell Proliferation Kit I, an MTT
assay (Roche Diagnostics, Indianapolis, IN). A positive GAPDH siR-
NA control siRNA (cat# D-001830-02-05) and a negative non-tar-
geting control siRNA (cat# D-001810-03-05) for these assays
were obtained from Dharmacon (Lafayette, CO) for use in these
experiments. Without optimization for maximal efﬁcacy, suppres-
sion of the vATPase target mRNA was approximately 70–80%, and
cellular viability under the conditions of transfection was approx-
imately 80–90% (Fig. 1). Similar data were not generated for the
218 bp dsRNA due to the limited capacity for cells to take up long
dsRNA and the tendency of long dsRNAs to trigger the innate
immune response in cultured cells, producing apoptosis (Gantier
and Williams, 2007).
2.3. Gene expression analysis
Mouse tissues or cultured cells were lysed in a guanidinium-
containing lysis buffer (proprietary to Asuragen, Austin, TX) added
to each sample at a 10 mL:1 g ratio. After disruption with a Poly-
tron homogenizer (mouse tissues) or cell lysis (cultured cells), tis-
sue samples were extracted with phenol:chloroform and RNA was
isolated with a KingFisher (Thermo Fisher Scientiﬁc, Waltham, MA)
instrument. QC analysis of RNA quality was performed using a
NanoDrop ND1000 Spectrophotometer (Thermo Fisher Scientiﬁc)
and an Agilent Bioanalyzer 2100.
RNA isolation and evaluation of vATPase gene expression in RNA
isolated from mouse stomach, duodenum, ileum, liver, kidney,
spleen, brain, and humerus tissues collected during the 28-day
studies was evaluated for all study animals under GLP conditions
via quantitative PCR (Taqman ABI assay Mm01343719_m1) with
gene expression normalized to levels of phosphoglycerate kinase
1 (PGK1; ABI assay Mm00435617_m1). Expression of these genes
in the selected tissues of untreated mice was conﬁrmed in a tissue
distribution study (Supplemental Fig. 1). An ileum tissue from a
male mouse in the 0.64 mg/kg 218 bp dsRNA treatment group
and two stomach samples from male mice in the 6.4 mg/kg
218 bp dsRNA treatment group did not amplify during the qPCR
analysis and were therefore excluded from the data analysis.
Fig. 1. siRNA Validation in Cultured Cells. (A) siRNA activity 24 h after transfection into mouse kidney cell line ATCC# CCL-139. vATPase mRNA expression was quantiﬁed by
TaqMan PCR as a ratio normalized to PGK1 mRNA. Data are expressed as a percent inhibition relative to untransfected cells. Test materials were siRNA duplexes 1, 3, 5, and 7
and an siRNA targeting mouse GAPDH. All bars evaluate vATPase expression, except that labeled GAPDH Knockdown, which is a positive control evaluating GAPDH
suppression in response to GAPDH siRNAs. (B) Evaluation of siRNA cytotoxicity in cultured mouse kidney cells. Approximately 24 h after siRNA transfection, cell viability was
evaluated via an MTT assay. Cell viability is expressed relative to that of untransfected cells. Control siRNA was a non-targeting siRNA and the GAPDH siRNA targeted mouse
GAPDH as described in Section 2.2.1.
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the deﬁnitive studies presented herein. A mouse 16 gene PCR array
was used to select the appropriate normalizer gene from the follow-
ing candidates: 18S ribosomal RNA, beta actin, beta glucuronidase,
beta-2 microglobulin, glyceraldehyde-3-phosphate dehydrogenase,
hydroxymethylbilane synthase, hypoxanthine guanine phosphori-
bosyl transferase 1, importin8, peptidylprolyl isomeraseA, phospho-
glyceratekinase1,polymerase (RNA) II (DNAdirected)polypeptideA,
ribosomal protein, large P2, TATA box binding protein, transferrin
receptor, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide, and ubiquitin C. Each PCR assay
utilized off the shelf ABI TaqMan assays (Life Technologies, Grand
Island, NY). Raw Ct values for each candidate gene were graphed
against the sample mean Ct, excluding genes with a Ct value above
32. The slope of this line and a Concordance Correlation Coefﬁcient
(CCC) were calculated for all candidates. The CCC identiﬁes candi-
dates that most closely track the sample mean. PGK1 was selected
as the normalizer gene candidate based on the highest slope and
CCC value of all evaluated normalizer gene candidates.
2.4. Statistical analysis
The continuous data (i.e., body weight, food consumption, clin-
ical chemistry, hematology, etc.) that were examined statisticallywere evaluated for homogeneity using Bartlett’s Test (Snedecor
and Cochran, 1967). If the data were homogeneous, a one-way
analysis of variance (ANOVA) (Snedecor and Cochran, 1967) was
performed, followed by Dunnett’s Test (Dunnett, 1955; Dunnett,
1964) on parameters showing a signiﬁcant effect by ANOVA. If
the data were non-homogeneous, a Kruskal–Wallis ANOVA was
performed, followed by the Mann–Whitney U Test to identify sta-
tistical signiﬁcance between groups. All tests were two-tailed,
except for gross and histopathological lesion evaluations, which
were one-tailed. Frequency of gross lesions and histopathological
data were examined statistically using a Chi-Square procedure. If
there was statistical signiﬁcance using the Chi-Square Test, each
treatment group was compared to the control group using a Fish-
er’s Exact Test (Hollander and Wolfe, 1973). For the Bartlett’s Test,
a probability (p) level60.001 was considered signiﬁcant. Data from
treated groups (and negative control) were compared to data from
the vehicle control group. Differences between treatment groups
with p values 60.05 were considered statistically signiﬁcant.
Prior to statistical analysis of the gene expression data, all ani-
mals from which PCR reactions did not amplify were eliminated (3
samples, described above). Gene expression data were analyzed in
males and females within each tissue using a one-way ANOVA
model according to a completely randomized design. Studentized
residuals were obtained to detect potential outliers in the dataset,
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are absent. Thus, most values are expected to be between ±3.
Extreme data points that are outside of the ±6 studentized residual
ranges were removed from the analysis. This resulted in removal of
a single female duodenum sample from the 0.64 mg/kg 218 bp
dsRNA group and a male (duodenum) and a female (ileum) sample
from the 21 mer dsRNA 0.45 mg/kg dose level as outliers. A Dun-
nett’s post hoc test was conducted on the remaining data to com-
pare all analyzed treatment groups (within each tissue by gender)
to the vehicle control (Dunnett, 1955; Dunnett, 1964). For all anal-
yses, statistical signiﬁcance is indicated as follows: p < 0.05 (⁄),
p < 0.01 (⁄⁄).
3. Results
3.1. Clinical observations
Each animal was observed for mortality, abnormalities, and
signs of pain and distress at least once daily and all animals were
healthy throughout the study. No test substance-related clinical
ﬁndings were observed during the course of the study. An absence
of test substance-related effects was conﬁrmed in a follow up
study in which female animals treated with the 218 bp dsRNA test
material at 65 mg/kg/day, showed no treatment-related effects on
mortality or clinical observations.Table 1
Mean Body Weights of Male Micea.
Group Body Weight (g) ± SD
Day 0 Day 7
Vehicle Control 29.8 ± 2.1 30.3 ± 1.9
RNA negative control 29.3 ± 2.0 30.5 ± 2.2
218-bp dsRNA
0.64 mg/kg/day
29.5 ± 1.7 29.5 ± 2.1
218-bp dsRNA
6.4 mg/kg/day
29.2 ± 3.0 30.2 ± 3.4
218-bp dsRNA
64 mg/kg/day
29.0 ± 2.8 30.4 ± 2.3
siRNA pool
0.45 mg/kg/day
29.2 ± 2.2 30.5 ± 1.7
siRNA pool
4.9 mg/kg/day
29.4 ± 1.6 30.2 ± 1.8
siRNA pool
48 mg/kg/day
29.5 ± 1.6 30.1 ± 1.6
a No statistically signiﬁcant differences were observed. n = 8 mice per group.
b Day 28 body weights were taken on fasted animals, thus lower weights reﬂect fasti
Table 2
Mean Body Weights of Female Mice.a
Group Body Weight (g) ± SD
Day 0 Day 7
Vehicle Control 25.9 ± 2.0 27.7 ± 1.5
RNA negative control 26.5 ± 2.1 27.4 ± 1.3
218-bp dsRNA
0.64 mg/kg/day
26.8 ± 1.3 27.5 ± 1.5
218-bp dsRNA
6.4 mg/kg/day
26.1 ± 1.4 27.3 ± 1.3
218-bp dsRNA
64 mg/kg/day
26.9 ± 1.7 28.3 ± 1.3
siRNA pool
0.45 mg/kg/day
26.5 ± 1.7 27.4 ± 1.5
siRNA pool
4.9 mg/kg/day
26.8 ± 2.0 27.5 ± 1.4
siRNA pool
48 mg/kg/day
26.8 ± 1.6 28.0 ± 2.0
a No statistically signiﬁcant differences were observed. n = 8 mice per group.
b Day 28 body weights were taken on fasted animals, thus lower weights reﬂect fasti3.2. Body weight and food consumption
Weekly body weights were comparable to controls across all
treatment groups and time points in both male and female mice
(Tables 1 and 2). Terminal body weights (study day 28) were taken
on animals fasted overnight prior to necropsy and the lower body
weights across all groups reﬂect fasting. Thus, there was no impact
of treatment on body weights.
Likewise, weekly food consumption was generally similar
across all treatment groups and time points in both male and
female mice (Tables 3 and 4). There were two statistically signiﬁ-
cant differences in food consumption in male mice at single inter-
vals, in the 6.4 mg/kg 218 bp dsRNA group (Study Week 2, Day 14)
and in the RNA negative control group (Study Week 4, Day 28).
However, these differences were limited to single intervals and
were not dose-related. Consequently, they were not considered
indicative of a treatment-related impact on food consumption.
3.3. Serum chemistry parameters
There were no treatment-related differences on serum chemis-
try parameters in either the 21-mer siRNA pool or the 218 bp
dsRNA treated groups (Tables 5 and 6). Statistically signiﬁcant dif-
ferences in serum chemistry parameters were observed (e.g., sev-
eral electrolytes and glucose in males and sodium, phosphorus,Day 14 Day 21 Day 28b
30.6 ± 2.1 30.9 ± 2.0 28.2 ± 1.5
32.1 ± 2.1 32.5 ± 1.4 29.6 ± 1.7
30.9 ± 2.2 31.7 ± 2.4 27.9 ± 2.1
31.6 ± 1.9 32.5 ± 2.4 29.0 ± 1.7
31.4 ± 2.7 31.8 ± 2.6 27.6 ± 2.5
31.1 ± 1.9 31.9 ± 1.9 28.5 ± 2.1
32.1 ± 1.9 32.8 ± 1.9 28.9 ± 2.2
31.6 ± 1.1 32.6 ± 1.6 29.4 ± 1.5
ng rather than body weight losses from treatment.
Day 14 Day 21 Day 28b
28.0 ± 1.6 28.2 ± 1.3 25.1 ± 1.4
28.4 ± 1.4 28.6 ± 1.9 25.4 ± 1.7
27.6 ± 1.6 27.8 ± 1.6 24.7 ± 1.2
27.9 ± 1.4 27.6 ± 1.9 24.7 ± 1.2
28.6 ± 1.6 29.6 ± 1.9 25.7 ± 1.4
27.8 ± 0.6 28.5 ± 0.8 24.7 ± 0.6
28.3 ± 1.3 29.2 ± 1.2 25.0 ± 1.7
28.3 ± 1.4 29.0 ± 1.3 25.1 ± 1.1
ng rather than body weight losses from treatment.
Table 3
Mean Food Consumption of Male Mice.a
Group Food Consumption (g/animal) ± SD
Day 7 Day 14 Day 21 Day 28
Vehicle Control 6.18 ± 0.39 5.45 ± 0.40 5.57 ± 0.42 4.63 ± 0.38
RNA negative control 5.99 ± 0.82 5.66 ± 0.30 5.82 ± 0.54 5.45 ± 0.42*
218-bp dsRNA
0.64 mg/kg/day
5.90 ± 0.46 5.61 ± 0.22 5.70 ± 0.83 4.54 ± 0.28
218-bp dsRNA
6.4 mg/kg/day
6.29 ± 0.45 6.16 ± 0.65* 5.90 ± 0.57 4.79 ± 0.45
218-bp dsRNA
64 mg/kg/day
5.69 ± 0.53 5.67 ± 0.51 5.22 ± 0.55 4.24 ± 0.73
siRNA pool
0.45 mg/kg/day
5.81 ± 0.60 5.33 ± 0.53 5.41 ± 0.37 4.59 ± 0.17
siRNA pool
4.9 mg/kg/day
5.84 ± 0.70 5.69 ± 0.42 5.47 ± 0.45 4.55 ± 0.38
siRNA pool
48 mg/kg/day
5.86 ± 0.56 5.73 ± 0.57 5.81 ± 0.49 4.70 ± 0.40
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the
control group.
* P 6 0.05.
a Data represent mean ± SD for 8 mice per group.
Table 4
Mean food consumption of female mice.a
Group Food Consumption (g/animal) ± SD
Day 7 Day 14 Day 21 Day 28
Vehicle Control 6.29 ± 0.91 5.50 ± 1.02 5.56 ± 0.75 No datab
RNA negative control 5.76 ± 1.01 5.29 ± 0.74 4.93 ± 0.80 4.82 ± 0.76
218-bp dsRNA
0.64 mg/kg/day
5.38 ± 0.87 5.15 ± 0.43 4.95 ± 0.33 4.20 ± 0.53
218-bp dsRNA
6.4 mg/kg/day
5.40 ± 0.28 5.08 ± 0.52 4.85 ± 0.54 4.16 ± 0.26
218-bp dsRNA
64 mg/kg/day
6.16 ± 1.26 5.79 ± 0.97 6.06 ± 1.22 4.76 ± 0.49
siRNA pool
0.45 mg/kg/day
5.23 ± 0.56 5.62 ± 0.81 5.39 ± 0.53 4.64 ± 1.12
siRNA pool
4.9 mg/kg/day
5.77 ± 0.81 5.68 ± 0.68 6.23 ± 1.10 4.68 ± 0.49
siRNA pool
48 mg/kg/day
5.47 ± 0.78 5.12 ± 0.24 5.43 ± 0.26 4.26 ± 0.20
a No statistically signiﬁcant differences were observed. Data represent mean ± SD
for 8 mice per group.
b Data inadvertently were not collected at this time point.
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not consistent across genders and were not dose-responsive and/
or test group values were similar to concurrent control groups.
All values were within laboratory historical control limits. Thus,
any observed differences were attributed to inter-animal variabil-
ity and not were not due to test substances.
3.4. Hematology
There were no treatment-related impacts of either the 21-mer
siRNA pool or the 218 bp dsRNA on hematology parameters (Tables
7 and 8). Higher total white blood cell counts (WBC) were observed
in females, including the 64 mg/kg 218 bp dsRNA group and all 21-
mer siRNA pool treated groups (Table 8). These higher values
appeared to be due to higher levels of lymphocytes and monocytes
(Table 9). These higher values did not correlate with any histopath-
ologic ﬁndings that would be anticipated to occur concomitantly
with physiologically relevant differences in WBC counts (e.g.,
spleens and lymph nodes appeared normal) and all values fell
within the laboratory historical control range (reﬂective of the nor-
mal physiological range). The observed WBC differences are most
likely attributable to stress, as animals were sacriﬁced in doseorder to prevent cross contamination of molecular biology samples
and blood cell values were signiﬁcantly higher in the last four nec-
ropsied groups (64 mg/kg 218 bp dsRNA and the 3 21-mer siRNA
pool treated groups). Animals were fasted overnight (with water
provided), resulting in some of the treated groups being fasted sub-
stantially longer than control animals. The animals necropsied
later in the day were also subjected to a greater duration of noise
and other stresses related to routine end of study laboratory activ-
ities being conducted in their midst. Stress is well accepted within
the pathology community as a contributing factor to increases in
WBC values in laboratory animals (Aulbach, 2013; Elliott, 2011).
Higher WBC counts were not observed in female mice adminis-
tered 65 mg/kg/day 218 bp dsRNA in a second 28-day repeat oral
dose study (6.87 ± 3.52  103 and 6.65 ± 3.27  103 per mm3 in
control and test groups, respectively) that employed random sacri-
ﬁce order, indicating that the initial result was not reproducible
and was likely an artifact attributable to stress. Based on the
weight of the evidence discussed above, the WBC count differences
were not attributed to either test substance and were not consid-
ered to be adverse.
3.5. Organ weights
There were no treatment-related effects on organ weights rela-
tive to terminal body weights (Tables 10 and 11). Statistically sig-
niﬁcant differences were also observed in relative organ weights
(e.g., ileum and kidney/body weight ratios in males, and duode-
num/body weight ratios in females). However, these differences
were generally not dose-responsive, not consistent between males
and females, and/or values were comparable to concurrent and/or
historical control groups. Absolute organ weights were also gener-
ally comparable between control group animals and treated ani-
mals with the exception of statistically signiﬁcant differences in
ileum (males) and duodenum (females) (Supplemental Data Tables
1 and 2). For the reasons cited above, the statistically signiﬁcant
differences in organ weights were neither considered adverse nor
treatment-related.
3.6. Pathology results
There were no treatment-related gross lesions (Tables 12 and
13) or microscopic ﬁndings (Tables 14 and 15) observed in the tox-
icological evaluation of the 21-mer siRNA pool or 218 bp dsRNA
test materials. Any gross or histologic changes that were noted in
individual animals were considered by the study pathologist to
be incidental ﬁndings and were not considered to be test sub-
stance-related, as there was no relationship between the test sub-
stance and the prevalence, severity, or histologic character of any
of the incidental tissue alterations.
3.7. Gene expression analysis
To explore the potential for gene suppression from the RNAi
mechanism following oral administration of dsRNAs to mice, vAT-
Pase gene expression was evaluated in selected systemic and gas-
trointestinal tissues of mice dosed with 218-bp dsRNA or the
siRNA pool (Fig. 2). Expression of vATPase mRNA was normalized
to expression of phosphoglycerate kinase 1 (internal control gene;
selected via 16 gene PCR array; see Section 2). Normalized expres-
sion values in each test group were compared to normalized
expression values from control mice. vATPase mRNA was most
highly expressed in brain, kidney, stomach, and spleen (in
descending order of abundance) and was moderately expressed
in other areas of the intestinal tract (Supplemental Fig. 1). There
was no suppression of vATPase expression in systemic tissues of
male or female mice, as evaluated in duodenum, ileum, liver, kid-
Table 5
Clinical Chemistry Evaluation of Male Mice Treated Orally with Indicated Agent and Dose for 28 Days.
Parameter Vehicle
control
RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Na (mM) 171 ± 3
(n = 8)
159 ± 2*
(n = 8)
168 ± 6
(n = 8)
169 ± 5
(n = 7)
170 ± 3
(n = 7)
168 ± 6
(n = 8)
168 ± 7
(n = 8)
170 ± 7
(n = 8)
K (mM) 12.6 ± 1.7
(n = 8)
14.4 ± 1.5
(n = 8)
12.3 ± 1.9
(n = 8)
11.3 ± 1.1
(n = 7)
13.3 ± 0.9
(n = 7)
12.0 ± 1.4
(n = 8)
10.0 ± 1.3*
(n = 8)
9.7 ± 1.1*
(n = 8)
Cl (mM) 123 ± 4
(n = 8)
112 ± 2*
(n = 8)
121 ± 4
(n = 8)
119 ± 4
(n = 7)
121 ± 5
(n = 7)
113 ± 1*
(n = 8)
115 ± 6*
(n = 8)
115 ± 5*
(n = 8)
Urea Nitrogen (mg/dL) 35 ± 14
(n = 8)
36 ± 12
(n = 8)
40 ± 13
(n = 7)
28 ± 6
(n = 7)
26 ± 5
(n = 7)
39 ± 17
(n = 8)
29 ± 7
(n = 8)
42 ± 22
(n = 8)
Glucose (mg/dL) 182 ± 32
(n = 8)
185 ± 24
(n = 8)
166 ± 15
(n = 8)
137 ± 28*
(n = 7)
150 ± 15
(n = 7)
171 ± 38
(n = 8)
131 ± 21*
(n = 8)
146 ± 34
(n = 8)
Creatinine (mg/dL) 0.4 ± 0.0
(n = 8)
0.4 ± 0.0
(n = 8)
0.4 ± 0.0
(n = 8)
0.4 ± 0.0
(n = 7)
0.4 ± 0.0
(n = 7)
0.4 ± 0.1
(n = 8)
0.4 ± 0.0
(n = 8)
0.4 ± 0.0
(n = 8)
Uric acid (mg/dL) 2.9 ± 0.3
(n = 8)
3.1 ± 0.3
(n = 8)
3.0 ± 0.4
(n = 8)
2.8 ± 0.2
(n = 7)
2.7 ± 0.3
(n = 7)
2.5 ± 1.1
(n = 8)
2.5 ± 0.3
(n = 8)
2.7 ± 0.4
(n = 8)
Triglycerides (mg/dL) 83 ± 35
(n = 8)
58 ± 12
(n = 8)
98 ± 36
(n = 8)
83 ± 22
(n = 7)
87 ± 27
(n = 7)
79 ± 35
(n = 8)
71 ± 18
(n = 8)
68 ± 31
(n = 8)
Cholesterol (mg/dL) 140 ± 25
(n = 7)
131 ± 35
(n = 8)
145 ± 31
(n = 8)
144 ± 8
(n = 7)
166 ± 54
(n = 7)
139 ± 42
(n = 8)
173 ± 34
(n = 8)
143 ± 38
(n = 8)
AST (U/L) 85 ± 7
(n = 8)
87 ± 15
(n = 8)
97 ± 21
(n = 8)
79 ± 14
(n = 7)
85 ± 23
(n = 7)
93 ± 15
(n = 8)
77 ± 16
(n = 8)
113 ± 77
(n = 8)
ALT (U/L) 30 ± 4
(n = 8)
33 ± 10
(n = 8)
31 ± 5
(n = 8)
29 ± 6
(n = 7)
29 ± 3
(n = 7)
32 ± 5
(n = 8)
26 ± 4
(n = 8)
35 ± 19
(n = 8)
GGT (U/L) 0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 7)
0 ± 0
(n = 7)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
ALP (U/L) 90 ± 34
(n = 8)
65 ± 15
(n = 8)
84 ± 10
(n = 8)
85 ± 28
(n = 7)
97 ± 27
(n = 7)
96 ± 23
(n = 8)
78 ± 16
(n = 8)
90 ± 29
(n = 8)
Total Bilirubin (mg/dL) 0.1 ± 0.1
(n = 8)
0.2 ± 0.0
(n = 8)
0.2 ± 0.1
(n = 8)
0.2 ± 0.0
(n = 7)
0.1 ± 0.0
(n = 7)
0.2 ± 0.1
(n = 8)
0.2 ± 0.1
(n = 8)
0.2 ± 0.0
(n = 8)
Total Protein (g/dL) 5.6 ± 0.4
(n = 8)
5.6 ± 0.2
(n = 8)
5.7 ± 0.4
(n = 8)
5.5 ± 0.2
(n = 7)
5.6 ± 0.2
(n = 7)
5.5 ± 0.4
(n = 8)
5.7 ± 0.3
(n = 8)
5.6 ± 0.2
(n = 7)
Albumin (g/dL) 3.4 ± 0.2
(n = 8)
3.4 ± 0.1
(n = 8)
3.3 ± 0.3
(n = 8)
3.3 ± 0.2
(n = 7)
3.4 ± 0.2
(n = 6)
3.4 ± 0.2
(n = 8)
3.3 ± 0.2
(n = 8)
3.3 ± 0.2
(n = 8)
Phosphorus (mg/dL) 10.5 ± 1.5
(n = 8)
9.1 ± 1.1*
(n = 8)
10.8 ± 0.6
(n = 8)
11.0 ± 1.2
(n = 7)
11.0 ± 0.9
(n = 7)
10.4 ± 0.6
(n = 8)
10.7 ± 1.2
(n = 8)
10.0 ± 0.7
(n = 8)
Calcium (mg/dL) 10.2 ± 0.4
(n = 8)
10.0 ± 0.2
(n = 8)
10.2 ± 0.1
(n = 8)
10.3 ± 0.3
(n = 7)
10.2 ± 0.2
(n = 7)
10.2 ± 0.3
(n = 8)
10.2 ± 0.3
(n = 8)
10.0 ± 0.4
(n = 8)
Globulin (g/dL) 2.2 ± 0.2
(n = 8)
2.2 ± 0.2
(n = 8)
2.3 ± 0.2
(n = 8)
2.0 ± 0.6
(n = 8)
2.4 ± 1.5
(n = 8)
2.2 ± 0.2
(n = 8)
2.3 ± 0.1
(n = 8)
2.3 ± 0.2
(n = 7)
Albumin/Globulin
ratio
1.5 ± 0.1
(n = 8)
1.5 ± 0.2
(n = 8)
1.4 ± 0.1
(n = 8)
1.5 ± 0.1
(n = 7)
1.5 ± 0.1
(n = 6)
1.6 ± 0.1
(n = 8)
1.4 ± 0.1
(n = 8)
1.4 ± 0.1
(n = 7)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
* P 6 0.05.
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(Fig. 2). Although statistically signiﬁcant increases in vATPase
expression were noted in several tissues (Fig. 2), this is likely to
represent biological variability (e.g., relatively modest differences
with large error bars, mostly limited to a single gender or test sub-
stance). Therefore it was concluded that these differences did not
represent evidence of gene suppression, the primary endpoint
being investigated in the gene expression evaluation. There was
also no suppression of vATPase levels in brain or kidneys of treated
animals (Fig. 2), the tissues with highest basal levels of vATPase
expression (Supplemental Fig. 1). The kidney is largely responsible
for clearance of systemically injected oligonucleotides (Molitoris
et al., 2009; Vaishnaw et al., 2010) and thus represents an organ
system that would see signiﬁcant exposure in the unlikely event
that appreciable absorption could occur following oral exposure.
Expression of vATPase was signiﬁcantly lower (50% reduction
relative to control) in the stomach of only the females that were
administered 64 mg/kg of the 218 bp dsRNA (Fig. 2), however,
the relationship of this result to treatment was uncertain because
it was noted in females only and signiﬁcant differences were not
noted at other dose levels with the 218-bp dsRNA or in the siRNA
treated groups. Furthermore, the observed difference in gene
expression was not accompanied by any changes in toxicologicalparameters (despite dsRNA targeting this gene producing toxicity
and lethality when consumed by corn rootworms), nor by any
impact on stomach histopathology and therefore did not appear
to be biologically relevant. Based on the weight of the evidence
the lower vATPase expression value in female mice treated with
64 mg/kg 218 bp dsRNA was considered equivocal and likely due
to experimental or biological variability, as there is no clear biolog-
ical basis for the ﬁnding being limited to a single gender (e.g.,
females only). Differential expression or activity of a dsRNA trans-
porter, such as those present in the nematode worm Caenorhabditis
elegans and selected insects (Huvenne and Smagghe, 2010) could
pose a reasonable explanation for an apparent gender difference,
however, in vivo evidence for the existence of a functional
dsRNA/small RNA uptake transporter in mammals is lacking. Given
the apparent lack of an active transport mechanism for exogenous
RNA uptake in mammals and the low likelihood of a putative gen-
der difference in passive uptake, differential dsRNA uptake (the
most plausible explanation for a putative gender difference) is
unlikely to explain the observed gender differences. Nevertheless,
to determine if the gene expression result in the stomach was
reproducible, an additional 28-day in vivo assessment was con-
ducted as described in the Section 2. The second study did not
reproduce the observed lower vATPase expression (Fig. 2) and it
Table 6
Clinical Chemistry Evaluation of Female Mice Treated Orally with Indicated Agent and Dose for 28 Days.
Parameter Vehicle
control
RNA negative control 218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Na (mM) 159 ± 2
(n = 8)
157 ± 2*
(n = 8)
157 ± 3
(n = 8)
157 ± 1$
(n = 8)
158 ± 1
(n = 8)
158 ± 2*
(n = 8)
152 ± 6*
(n = 8)
157 ± 2*
(n = 8)
K (mM) 11.1 ± 0.9
(n = 8)
12.1 ± 0.9
(n = 8)
12.0 ± 1.4
(n = 8)
11.7 ± 1.0
(n = 8)
12.2 ± 1.1
(n = 8)
10.8 ± 1.4
(n = 8)
10.8 ± 1.0
(n = 8)
11.0 ± 0.7
(n = 8)
Cl (mM) 115 ± 2
(n = 8)
114 ± 2
(n = 8)
115 ± 2
(n = 8)
114 ± 2
(n = 8)
115 ± 2
(n = 8)
113 ± 2
(n = 8)
113 ± 4
(n = 8)
114 ± 2
(n = 8)
Urea Nitrogen (mg/dL) 25 ± 4
(n = 8)
21 ± 3
(n = 8)
21 ± 3
(n = 8)
22 ± 3
(n = 8)
22 ± 2
(n = 8)
22 ± 5
(n = 8)
25 ± 15
(n = 8)
19 ± 3
(n = 8)
Glucose (mg/dL) 127 ± 17
(n = 8)
128 ± 16
(n = 8)
106 ± 15
(n = 8)
117 ± 19
(n = 8)
110 ± 12
(n = 8)
115 ± 14
(n = 8)
119 ± 24
(n = 8)
104 ± 18
(n = 8)
Creatinine (mg/dL) 0.4 ± 0.0
(n = 8)
0.4 ± 0.0
(n = 8)
0.3 ± 0.0
(n = 8)
0.3 ± 0.1
(n = 7)
0.3 ± 0.1
(n = 7)
0.4 ± 0.0
(n = 8)
0.3 ± 0.0
(n = 8)
0.3 ± 0.0
(n = 8)
Uric acid
(mg/dL)
2.3 ± 0.3
(n = 8)
2.5 ± 0.3
(n = 8)
2.2 ± 0.3
(n = 8)
2.2 ± 0.3
(n = 8)
2.2 ± 0.2
(n = 8)
2.1 ± 0.2
(n = 8)
2.1 ± 0.2
(n = 8)
1.9 ± 0.2*
(n = 8)
Triglycerides (mg/dL) 58 ± 25
(n = 8)
57 ± 16
(n = 8)
63 ± 14
(n = 8)
68 ± 9
(n = 8)
61 ± 30
(n = 8)
62 ± 18
(n = 8)
54 ± 27
(n = 8)
59 ± 12
(n = 8)
Cholesterol (mg/dL) 91 ± 14
(n = 8)
107 ± 15
(n = 8)
87 ± 19
(n = 8)
98 ± 22
(n = 8)
97 ± 23
(n = 8)
105 ± 14
(n = 8)
96 ± 13
(n = 8)
110 ± 16
(n = 8)
AST (U/L) 112 ± 48
(n = 8)
109 ± 37
(n = 8)
96 ± 42
(n = 8)
113 ± 24
(n = 8)
105 ± 40
(n = 8)
119 ± 56
(n = 8)
114 ± 47
(n = 8)
93 ± 18
(n = 8)
ALT (U/L) 33 ± 4
(n = 8)
33 ± 4
(n = 8)
28 ± 6
(n = 8)
34 ± 7
(n = 8)
31 ± 5
(n = 8)
29 ± 4
(n = 8)
31 ± 10
(n = 8)
30 ± 6
(n = 8)
GGT (U/L) 0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
0 ± 0
(n = 8)
ALP (U/L) 95 ± 41
(n = 8)
76 ± 21
(n = 8)
78 ± 14
(n = 8)
111 ± 24
(n = 8)
100 ± 33
(n = 8)
140 ± 94$
(n = 8)
77 ± 14
(n = 8)
83 ± 20
(n = 8)
Total Bilirubin (mg/
dL)
0.2 ± 0.1
(n = 8)
0.2 ± 0.1
(n = 8)
0.1 ± 0.1
(n = 8)
0.1 ± 0.0
(n = 7)
0.2 ± 0.1
(n = 7)
0.1 ± 0.1
(n = 8)
0.1 ± 0.0
(n = 8)
0.1 ± 0.0
(n = 8)
Total Protein (g/dL) 5.5 ± 0.3
(n = 8)
5.6 ± 0.2
(n = 8)
5.4 ± 0.2
(n = 8)
5.6 ± 0.3
(n = 8)
5.6 ± 0.4
(n = 8)
5.7 ± 0.3
(n = 8)
5.2 ± 0.2
(n = 8)
5.3 ± 0.1
(n = 8)
Albumin (g/dL) 3.5 ± 0.2
(n = 8)
3.6 ± 0.2
(n = 8)
3.4 ± 0.1
(n = 8)
3.5 ± 0.2
(n = 8)
3.5 ± 0.3
(n = 8)
3.5 ± 0.2
(n = 8)
3.3 ± 0.1
(n = 8)
3.4 ± 0.1
(n = 8)
Phosphorus (mg/dL) 10.2 ± 0.5
(n = 8)
8.8 ± 0.4*
(n = 8)
10.3 ± 0.5
(n = 8)
9.9 ± 0.7
(n = 8)
9.6 ± 0.7
(n = 8)
9.7 ± 1.2
(n = 8)
9.7 ± 0.8
(n = 8)
9.5 ± 1.0
(n = 8)
Calcium (mg/dL) 10.0 ± 0.2
(n = 8)
10.1 ± 0.3
(n = 8)
10.0 ± 0.2
(n = 8)
10.2 ± 0.3
(n = 8)
10.2 ± 0.1
(n = 8)
10.3 ± 0.2
(n = 8)
9.8 ± 0.5
(n = 8)
10.2 ± 0.2
(n = 8)
Globulin (g/dL) 2.0 ± 0.2
(n = 8)
2.1 ± 0.1
(n = 8)
1.9 ± 0.1
(n = 8)
2.1 ± 0.2
(n = 8)
2.1 ± 0.1
(n = 8)
2.2 ± 0.2
(n = 8)
1.9 ± 0.1
(n = 8)
1.9 ± 0.1
(n = 8)
Albumin/
Globulin ratio
1.7 ± 0.1
(n = 8)
1.7 ± 0.1
(n = 8)
1.8 ± 0.1
(n = 8)
1.7 ± 0.1
(n = 8)
1.7 ± 0.1
(n = 8)
1.6 ± 0.1
(n = 8)
1.7 ± 0.1
(n = 8)
1.7 ± 0.1
(n = 8)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
Kruskal–Wallis ANOVA + Mann–Whitney U test (Two-Sided) to compare each test group to the control group.
* P 6 0.05.
$ P 6 0.05.
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cal was correct. Based on the lack of toxicological or histopatholo-
gical correlates and the lack of reproducibility, the lower vATPase
expression observed in the female stomach in the initial study
was considered not to be biologically relevant and was considered
to be unrelated to treatment.
4. Discussion
The studies presented herein were designed to evaluate the
robustness of mammalian barriers to exogenous dsRNA. This study
uses toxicity and target gene expression as surrogate measures of
any biologically meaningful absorption/biodistribution or activity
of ingested dsRNA. This is because any relevant impact of an
absorbed nucleic acid on gene expression (e.g., ability to reach a
target and trigger on-target or off-target gene suppression) would
manifest itself as a physiological impact. These potential physio-
logical impacts were evaluated in this study through a robust
assessment of animal health and toxicological parameters. A strong
weight of the evidence supports a conclusion of negligible uptake
of ingested RNA by mammals (Dickinson et al., 2013; Petrick
et al., 2013; Snow et al., 2013; Witwer et al., 2013). Although thesepeer reviewed studies evaluated uptake of mature, plant-derived
miRNAs, such data represent an evaluation of uptake potential
for the functional portion of these double stranded RNAs. A single
report has been published to date that claims potent and speciﬁc
physiological impacts in animals (decrease in LDLRAP1 protein
and increase in LDL) resulting from consumption of a plant small
RNA (rice miR168a) in the diet (Zhang et al., 2012a). These results
were surprising for at least two reasons. First, the aforementioned
barriers to oligonucleotide drug delivery by the oral route have
posed an insurmountable challenge to the development of oral
RNA therapeutics to date. Second, the dose levels used to achieve
efﬁcacy of parenterally administered RNA drugs (i.e., mg/kg/day;
typically chemically stabilized and/or formulated) and the levels
of endogenous plant small RNAs consumed in foods (i.e., ng/kg/
day) differ by several orders of magnitude. Suggestions of a biolog-
ical effect at these oral exposure levels (i.e., ng/kg/day) that are
much lower than required for parenteral (i.e., non-oral) activity
of therapeutic RNAs (i.e., mg/kg/day) is counter to the basic princi-
ples of pharmacology and toxicology. Contamination has been
cited as a possible explanation for the reported detection of
ingested plant small RNAs in mammals (Tosar et al., 2014; Zhang
et al., 2012b). A robust rice feeding experiment was conducted in
Table 7
Selected Hematology Parameters in Male Mice (Mean ± SD).
Parameter Vehicle control RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Platelets (103/ll) 1486 ± 289
(n = 7)
1759 ± 360
(n = 7)
1649 ± 261
(n = 8)
1384 ± 353
(n = 6)
1398 ± 321
(n = 7)
1609 ± 216
(n = 6)
1558 ± 144
(n = 7)
1554 ± 251
(n = 6)
White Blood Cells (103/ll) 8.5 ± 2.5
(n = 8)
7.3 ± 2.9
(n = 7)
7.2 ± 2.5
(n = 8)
11.0 ± 4.2
(n = 6)
9.6 ± 3.1
(n = 8)
7.8 ± 2.9
(n = 6)
8.6 ± 1.3
(n = 8)
5.6 ± 2.4
(n = 8)
Red Blood Cells (106/ll) 10.41 ± 0.67
(n = 8)
10.27 ± 0.60
(n = 7)
10.29 ± 0.76
(n = 8)
10.46 ± 0.42
(n = 6)
10.21 ± 0.47
(n = 8)
10.54 ± 0.45
(n = 6)
10.84 ± 0.57
(n = 8)
10.96 ± 0.48
(n = 8)
Hemoglobin (g/dL) 16.1 ± 0.8
(n = 8)
15.9 ± 0.9
(n = 7)
16.2 ± 1.1
(n = 8)
16.2 ± 0.7
(n = 6)
14.3 ± 4.4
(n = 8)
16.3 ± 0.7
(n = 6)
16.7 ± 0.8
(n = 8)
16.8 ± 0.7
(n = 8)
Hematocrit (%) 53.3 ± 2.6
(n = 8)
54.0 ± 3.1
(n = 7)
52.7 ± 3.2
(n = 8)
52.9 ± 2.3
(n = 6)
51.4 ± 3.5
(n = 8)
53.2 ± 2.0
(n = 6)
54.9 ± 3.0
(n = 8)
55.4 ± 3.2
(n = 8)
Mean Corpuscular Volume (fL) 51.3 ± 1.5
(n = 8)
52.6 ± 1.0
(n = 7)
51.3 ± 1.6
(n = 8)
50.6 ± 1.7
(n = 6)
50.3 ± 1.4
(n = 8)
50.5 ± 0.7
(n = 6)
50.6 ± 1.5
(n = 8)
50.6 ± 1.2
(n = 8)
Mean Corpuscular Hemoglobin
(pg)
15.5 ± 0.5
(n = 8)
15.4 ± 0.5
(n = 7)
15.7 ± 0.4
(n = 8)
15.5 ± 0.4
(n = 6)
14.0 ± 4.3
(n = 8)
15.5 ± 0.4
(n = 6)
15.5 ± 0.5
(n = 8)
15.4 ± 0.3
(n = 8)
MCH Concentration (g/dL) 30.2 ± 0.5
(n = 8)
29.3 ± 0.7$
(n = 7)
30.6 ± 0.6
(n = 8)
30.6 ± 0.5
(n = 6)
27.9 ± 8.4
(n = 8)
30.6 ± 0.6
(n = 6)
30.5 ± 0.6
(n = 8)
30.4 ± 0.7
(n = 8)
Kruskal–Wallis ANOVA + Mann–Whitney U test (Two-Sided) to compare each test group to the control group.
$P 6 0.05.
Table 8
Selected hematology parameters in female mice (mean ± SD).
Parameter Vehicle control RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Platelets (103/ll) 1300 ± 239
(n = 7)
1312 ± 72
(n = 3)
1277 ± 67
(n = 4)
1127 ± 237
(n = 4)
1112 ± 505
(n = 7)
1327 ± 294
(n = 5)
1149 ± 234
(n = 5)
1293 ± 216
(n = 4)
White Blood Cells (103/ll) 6.2 ± 1.1
(n = 7)$$
5.6 ± 2.4
(n = 4)
6.5 ± 2.3
(n = 5)
7.5 ± 0.7
(n = 4)
10.5 ± 3.2*,$$
(n = 7)
10.3 ± 2.7*
(n = 5)
10.8 ± 1.3*
(n = 5)
11.8 ± 3.2*
(n = 4)
Red Blood Cells (106/ll) 10.45 ± 0.36
(n = 7)
10.11 ± 1.06
(n = 4)
10.23 ± 0.23
(n = 5)
10.64 ± 0.27
(n = 4)
10.28 ± 0.37
(n = 7)
10.44 ± 0.55
(n = 5)
10.49 ± 0.54
(n = 5)
10.68 ± 0.47
(n = 4)
Hemoglobin (g/dL) 16.2 ± 0.4
(n = 7)
15.9 ± 1.3
(n = 4)
15.8 ± 0.4
(n = 5)
16.5 ± 0.9
(n = 4)
16.0 ± 0.8
(n = 7)
16.3 ± 0.8
(n = 5)
16.7 ± 1.0
(n = 5)
13.3 ± 7.4
(n = 4)
Hematocrit (%) 52.7 ± 1.7
(n = 7)
52.6 ± 3.8
(n = 4)
50.5 ± 1.8
(n = 5)
53.6 ± 1.8
(n = 4)
51.5 ± 2.2
(n = 7)
52.7 ± 3.1
(n = 5)
53.0 ± 3.0
(n = 5)
54.2 ± 1.4
(n = 4)
Mean Corpuscular Volume (fL) 50.4 ± 1.5
(n = 7)
52.1 ± 2.0
(n = 4)
49.3 ± 1.2
(n = 5)
50.4 ± 1.0
(n = 4)
50.2 ± 1.6
(n = 7)
50.5 ± 1.4
(n = 5)
50.5 ± 0.8
(n = 5)
50.7 ± 1.0
(n = 4)
Mean Corpuscular Hemoglobin
(pg)
15.5 ± 0.3
(n = 7)
15.7 ± 0.4
(n = 4)
15.5 ± 0.3
(n = 5)
15.5 ± 0.4
(n = 4)
15.6 ± 0.6
(n = 7)
15.6 ± 0.4
(n = 5)
15.9 ± 0.2
(n = 5)
12.4 ± 6.9
(n = 4)
MCH Concentration (g/dL) 30.7 ± 0.5
(n = 7)
30.2 ± 0.6
(n = 4)
31.3 ± 0.6
(n = 5)
30.8 ± 0.9
(n = 4)
31.1 ± 1.2
(n = 7)
31.0 ± 0.4
(n = 5)
31.4 ± 0.5
(n = 5)
24.5 ± 13.7
(n = 4)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
* P 6 0.05.
$$ WBC levels in an in vivo follow up assessment were 6.87 ± 3.52  103 and 6.65 ± 3.27  103 per mm3 in control and 65 mg/kg 218 bp dsRNA female test groups,
respectively (data tables not shown).
Table 9
Selected Leukocyte Parameters from Male and Female Mice (Statistically Signiﬁcant Findings Only).
Parameter Vehicle
control
RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Males: Lymphocytes, Absolute
(x103/mm3)
5.29 ± 1.78
(n = 8)
4.75 ± 2.42
(n = 7)
4.39 ± 1.04
(n = 8)
7.23 ± 3.08
(n = 6)
6.21 ± 2.75
(n = 8)
5.90 ± 2.26
(n = 6)
6.28 ± 1.35
(n = 8)
3.63 ± 2.03
(n = 8)
Males: Monocytes, Absolute
(x103/mm3)
0.12 ± 0.05
(n = 8)
0.11 ± 0.06
(n = 7)
0.09 ± 0.07
(n = 8)
0.13 ± 0.10
(n = 6)
0.11 ± 0.05
(n = 8)
0.12 ± 0.09
(n = 6)
0.10 ± 0.04
(n = 8)
0.08 ± 0.06
(n = 8)
Females: Lymphocytes, Absolute
(x103/mm3)
3.80 ± 1.21
(n = 7)
4.17 ± 2.07
(n = 4)
4.42 ± 1.45
(n = 5)
5.34 ± 1.11
(n = 4)
7.51 ± 2.55*
(n = 7)
7.33 ± 1.89*
(n = 5)
7.99 ± 1.49*
(n = 5)
8.99 ± 2.47*
(n = 4)
Females: Monocytes, Absolute
(x103/mm3)
0.05 ± 0.01
(n = 7)
0.08 ± 0.02
(n = 4)
0.08 ± 0.04
(n = 5)
0.07 ± 0.04
(n = 4)
0.15 ± 0.06*
(n = 7)
0.14 ± 0.04*
(n = 5)
0.14 ± 0.05*
(n = 5)
0.16 ± 0.05*
(n = 4)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
Note: N.D. = not detected, no samples available for analysis.
* P 6 0.05.
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Table 10
Terminal Body (g) and Relative Organ Weights (%) of Male Mice.
Tissue Vehicle
control
RNA negative control 218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/day 0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/day
BodyWeight (fasted) 28.2 ± 1.5
(n = 8)
29.6 ± 1.7
(n = 8)
27.9 ± 2.1
(n = 8)
29.0 ± 1.7
(n = 8)
27.6 ± 2.5
(n = 8)
28.5 ± 2.1
(n = 8)
28.9 ± 2.2
(n = 8)
29.4 ± 1.5
(n = 8)
Adrenal gland/BW 0.029 ± 0.014
(n = 8)
0.031 ± 0.011
(n = 8)
0.030 ± 0.012
(n = 8)
0.027 ± 0.005
(n = 8)
0.030 ± 0.014
(n = 8)
0.031 ± 0.007
(n = 8)
0.029 ± 0.009
(n = 8)
0.031 ± 0.018
(n = 8)
Brain/BW 1.744 ± 0.080
(n = 8)
1.653 ± 0.100
(n = 8)
1.763 ± 0.102
(n = 8)
1.693 ± 0.083
(n = 8)
1.762 ± 0.107
(n = 8)
1.666 ± 0.142
(n = 8)
1.649 ± 0.120
(n = 8)
1.639 ± 0.080
(n = 8)
Heart/BW 0.568 ± 0.073
(n = 8)
0.624 ± 0.087
(n = 8)
0.591 ± 0.067
(n = 8)
0.570 ± 0.038
(n = 8)
0.564 ± 0.075
(n = 8)
0.558 ± 0.058
(n = 8)
0.563 ± 0.040
(n = 8)
0.569 ± 0.055
(n = 8)
Kidney/BW 2.061 ± 0.195
(n = 8)
1.908 ± 0.117
(n = 8)
2.025 ± 0.245
(n = 8)
1.916 ± 0.082
(n = 8)
1.953 ± 0.069
(n = 8)
1.840 ± 0.151$
(n = 8)
1.589 ± 0.517$
(n = 8)
1.876 ± 0.138$
(n = 8)
Liver/BW 5.011 ± 0.399
(n = 8)
4.779 ± 0.627
(n = 8)
4.739 ± 0.348
(n = 8)
4.636 ± 0.239
(n = 8)
4.700 ± 0.329
(n = 8)
4.625 ± 0.220
(n = 8)
4.654 ± 0.356
(n = 8)
4.544 ± 0.252
(n = 8)
Spleen/BW 0.288 ± 0.068
(n = 8)
0.290 ± 0.072
(n = 8)
0.296 ± 0.064
(n = 8)
0.325 ± 0.108
(n = 8)
0.321 ± 0.074
(n = 8)
0.297 ± 0.063
(n = 8)
0.284 ± 0.045
(n = 8)
0.279 ± 0.101
(n = 8)
Testis/BW 0.715 ± 0.060
(n = 8)
0.808 ± 0.093
(n = 8)
0.757 ± 0.070
(n = 8)
0.792 ± 0.046
(n = 8)
0.831 ± 0.100
(n = 8)
0.762 ± 0.099
(n = 8)
0.778 ± 0.098
(n = 8)
0.748 ± 0.071
(n = 8)
Thymus/BW 0.145 ± 0.033
(n = 8)
0.174 ± 0.037
(n = 8)
0.170 ± 0.023
(n = 8)
0.149 ± 0.041
(n = 8)
0.149 ± 0.026
(n = 8)
0.169 ± 0.038
(n = 8)
0.137 ± 0.022
(n = 8)
0.127 ± 0.015
(n = 8)
Humerus/BW 0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
Duodenum/
BW
0.019 ± 0.003
(n = 8)
0.019 ± 0.003
(n = 8)
0.018 ± 0.004
(n = 8)
0.020 ± 0.003
(n = 8)
0.019 ± 0.003
(n = 8)
0.019 ± 0.003
(n = 8)
0.018 ± 0.003
(n = 8)
0.020 ± 0.002
(n = 8)
Jejunum/BW 0.018 ± 0.002
(n = 8)
0.016 ± 0.002
(n = 8)
0.018 ± 0.002
(n = 8)
0.018 ± 0.004
(n = 8)
0.016 ± 0.004
(n = 8)
0.017 ± 0.003
(n = 8)
0.017 ± 0.002
(n = 8)
0.016 ± 0.002
(n = 8)
Ileum/BW 0.017 ± 0.001
(n = 8)
0.015 ± 0.004
(n = 8)
0.016 ± 0.003
(n = 8)
0.015 ± 0.003
(n = 8)
0.013 ± 0.003*
(n = 8)
0.016 ± 0.004
(n = 8)
0.014 ± 0.003*
(n = 8)
0.015 ± 0.004
(n = 8)
Colon/BW 0.012 ± 0.001
(n = 8)
0.012 ± 0.003
(n = 8)
0.012 ± 0.002
(n = 8)
0.011 ± 0.002
(n = 8)
0.011 ± 0.003
(n = 8)
0.011 ± 0.003
(n = 8)
0.011 ± 0.003
(n = 8)
0.010 ± 0.003
(n = 8)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
Kruskal–Wallis ANOVA + Mann–Whitney U Test (Two-Sided) to compare each test group to the control group.
* P 6 0.05.
$ P 6 0.05.
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leagues and this study was unable to reproduce the reported phys-
iological change in LDLRAP1 protein (Dickinson et al., 2013).
However, Dickinson et al. were able to replicate the LDL results
observed by Zhang and colleagues, albeit in the absence of any
apparent miR168a uptake and only in a group of animals receiving
a nutritionally unbalanced diet consisting of mostly rice (but not
when nutrition was controlled for). This study demonstrated that
the ﬁndings of Zhang and colleagues were confounded by employ-
ing a 100% raw rice feeding regimen, which is nutritionally imbal-
anced. Furthermore, changes in LDL levels observed by both
Dickinson and colleagues and Zhang and colleagues are consistent
with the known impact of diet composition on blood cholesterol
levels in mice during fasting and re-feeding (Ryu et al., 2005).
Snow et al. (2013), Witwer et al. (2013) and Dickinson et al.
(2013) did not observe biologically meaningful uptake of plant
small RNAs in test animals after feeding (humans, primates, or
mice), as measured through quantiﬁcation of mature plant miRNAs.
As discussed above, mature miRNAs serve as a surrogate for func-
tionally active miRNAs. Although differing in the precursors from
which they are derived, both plant siRNAs and miRNAs are double
stranded small RNAs in the size range of 21–27 nucleotides that
are cleaved from longer dsRNA precursors and regulate gene
expression (Hammond, 2005; Liu et al., 2009; Zamore et al.,
2000). Measurement of plant miRNAs after ingestion therefore
serves as a surrogate for uptake of plant small RNAs. Snow and col-
leagues concluded that absorption and delivery of dietary plant
miRNAs in model animals is neither a robust nor a frequent occur-
rence (Snow et al., 2013), whileWitwer and colleagues indicate that
their results do not support general and consistent uptake of dietary
plant miRNAs (Witwer et al., 2013).The weight of the scientiﬁc evidence assembled by 3 indepen-
dent groups with studies designed to investigate the potential for
signiﬁcant uptake of speciﬁc small RNAs from the diet demon-
strates that the results of Zhang and colleagues cannot be repli-
cated. A recent review article has reviewed the weight of the
evidence on this topic and states that, ‘‘In light of these uniformly
negative ﬁndings, it is important to examine whether physiologi-
cally relevant concentrations of miRNA could be achieved at all,
given the limited number of copies present for even the most
highly expressed miRNAs in animal- or plant-derived dietary items
(Cottrill and Chan, 2014).’’
RNA interference is a sequence-dependent mechanism for reg-
ulation of gene expression by small RNAs and thus, sequence-
dependent off-target gene suppression has been observed using
in vitro systems (Jackson et al., 2003). Studies in this research area
have utilized transfection reagents and high doses of RNA. Conse-
quently, these studies have limited predictive value for determin-
ing the potential for sequence-dependent off-target gene
suppression impacts of dietary RNA exposure in higher organisms.
In contrast, when many siRNAs are present (in an in vitro system),
as would occur after processing of a long dsRNA within the plant or
in an organism having consumed plant material (assuming absorp-
tion), off-target effects tend to be eliminated by the dilution effect
of a complex siRNA pool (Hannus et al., 2014). Despite these con-
siderations, the use of bioinformatics to predict off target gene sup-
pression has been commonly proposed as a tool to predict the
potential for impact of ingested small RNAs on mammalian sys-
tems. Bioinformatics, however, has limited predictive value for
RNA food safety evaluation because other factors besides simple
sequence identity are also critical to determining putative activity
of any absorbed RNAs, as described by Liu et al. (2013).
Table 11
Terminal Body (g) and Relative Organ Weights (%) of Female Mice.
Tissue Vehicle control RNA negative control 218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/day
Body Weight (fasted) 25.1 ± 1.4
(n = 8)
25.4 ± 1.7
(n = 8)
24.7 ± 1.2
(n = 8)
24.7 ± 1.2
(n = 8)
25.7 ± 1.4
(n = 8)
24.7 ± 0.6
(n = 8)
25.0 ± 1.7
(n = 8)
25.1 ± 1.1
(n = 8)
Adrenal gland/BW 0.048 ± 0.016
(n = 8)
0.057 ± 0.011
(n = 8)
0.048 ± 0.014
(n = 8)
0.047 ± 0.012
(n = 8)
0.048 ± 0.018
(n = 8)
0.053 ± 0.011
(n = 8)
0.043 ± 0.012
(n = 8)
0.046 ± 0.007
(n = 8)
Brain/BW 1.865 ± 0.138
(n = 8)
1.896 ± 0.132
(n = 8)
1.982 ± 0.141
(n = 8)
1.957 ± 0.112
(n = 8)
1.913 ± 0.087
(n = 8)
2.044 ± 0.105
(n = 8)
2.289 ± 0.795
(n = 8)
2.032 ± 0.132
(n = 8)
Heart/BW 0.594 ± 0.057
(n = 8)
0.588 ± 0.075
(n = 8)
0.554 ± 0.032
(n = 8)
0.552 ± 0.044
(n = 8)
0.569 ± 0.047
(n = 8)
0.535 ± 0.036
(n = 8)
0.611 ± 0.093
(n = 8)
0.566 ± 0.085
(n = 8)
Kidney/BW 1.880 ± 0.782
(n = 8)
1.498 ± 0.088
(n = 8)
1.504 ± 0.155
(n = 8)
1.551 ± 0.112
(n = 8)
1.553 ± 0.153
(n = 8)
1.651 ± 0.125
(n = 8)
1.537 ± 0.075
(n = 8)
1.547 ± 0.109
(n = 8)
+Liver/BW 4.380 ± 0.325
(n = 8)
4.416 ± 0.289
(n = 8)
4.327 ± 0.224
(n = 8)
4.342 ± 0.216
(n = 8)
4.399 ± 0.194
(n = 8)
4.388 ± 0.314
(n = 8)
4.563 ± 0.869
(n = 8)
4.242 ± 0.170
(n = 8)
Spleen/BW 0.300 ± 0.066
(n = 8)
0.333 ± 0.030
(n = 8)
0.366 ± 0.085
(n = 8)
0.376 ± 0.064
(n = 8)
0.372 ± 0.070
(n = 8)
0.335 ± 0.066
(n = 8)
0.368 ± 0.058
(n = 8)
0.329 ± 0.074
(n = 8)
Ovaries/BW 0.111 ± 0.027
(n = 8)
0.119 ± 0.030
(n = 8)
0.144 ± 0.031
(n = 8)
0.128 ± 0.027
(n = 8)
0.136 ± 0.038
(n = 8)
0.130 ± 0.022
(n = 8)
0.134 ± 0.017
(n = 8)
0.129 ± 0.031
(n = 8)
Uterus/BW 0.545 ± 0.170
(n = 8)
0.739 ± 0.235
(n = 8)
0.717 ± 0.307
(n = 8)
0.629 ± 0.204
(n = 8)
0.677 ± 0.248
(n = 8)
0.771 ± 0.248
(n = 8)
0.710 ± 0.214
(n = 8)
0.593 ± 0.127
(n = 8)
Thymus gland/BW 0.192 ± 0.072
(n = 8)
0.179 ± 0.055
(n = 8)
0.193 ± 0.042
(n = 8)
0.210 ± 0.025
(n = 8)
0.195 ± 0.022
(n = 8)
0.218 ± 0.043
(n = 8)
0.179 ± 0.072
(n = 8)
0.221 ± 0.055
(n = 8)
Stomach/BW 1.156 ± 0.165
(n = 8)
1.316 ± 0.139
(n = 8)
1.259 ± 0.265
(n = 8)
1.257 ± 0.206
(n = 8)
1.224 ± 0.143
(n = 8)
1.261 ± 0.215
(n = 8)
1.226 ± 0.245
(n = 8)
1.543 ± 0.908
(n = 8)
Humerus/BW 0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
0.004 ± 0.001
(n = 8)
0.003 ± 0.002
(n = 8)
0.003 ± 0.001
(n = 8)
0.003 ± 0.001
(n = 8)
Duodenum/BW 0.018 ± 0.001
(n = 8)
0.020 ± 0.005
(n = 8)
0.022 ± 0.003*
(n = 8)
0.021 ± 0.002*
(n = 8)
0.019 ± 0.002
(n = 8)
0.021 ± 0.004
(n = 8)
0.021 ± 0.004
(n = 8)
0.020 ± 0.002*
(n = 8)
Jejunum/BW 0.018 ± 0.003
(n = 8)
0.019 ± 0.003
(n = 8)
0.020 ± 0.004
(n = 8)
0.018 ± 0.001
(n = 8)
0.018 ± 0.002
(n = 8)
0.017 ± 0.002
(n = 8)
0.017 ± 0.003
(n = 8)
0.017 ± 0.003
(n = 8)
Ileum/BW 0.015 ± 0.004
(n = 8)
0.017 ± 0.003
(n = 8)
0.017 ± 0.004
(n = 8)
0.017 ± 0.004
(n = 8)
0.015 ± 0.004
(n = 8)
0.015 ± 0.003
(n = 8)
0.016 ± 0.003
(n = 8)
0.016 ± 0.003
(n = 8)
Colon/BW 0.011 ± 0.001
(n = 8)
0.013 ± 0.004
(n = 8)
0.011 ± 0.002
(n = 8)
0.012 ± 0.002
(n = 8)
0.011 ± 0.002
(n = 8)
0.011 ± 0.002
(n = 8)
0.011 ± 0.002
(n = 8)
0.011 ± 0.003
(n = 8)
Statistics: ANOVA + Dunnett’s test (Two-Sided) to compare each test group to the control group.
* P 6 0.05.
Table 12
Gross Pathology Evaluation of Male Mice, Out of 8 Animals Evaluated.
Tissue: Finding Vehicle
control
RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Adrenal Glands: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Bone, Femur: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Bone, Humerus: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Brain, Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Colon: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Duodenum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Heart: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Ileum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Jejunum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Kidneys: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Liver: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Lung: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Lymph Node, Mesenteric:
Normal
8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Muscle, Gastrocnemius:
Normal
8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Pancreas: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Cervical: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Lumbar: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Thoracic: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spleen: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Stomach: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Testis: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Thymus: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Urinary Bladder: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
18 J.S. Petrick et al. / Regulatory Toxicology and Pharmacology 71 (2015) 8–23
Table 13
Gross Pathology Evaluation of Female Mice, Out of 8 Animals Evaluated.
Tissue: Finding Vehicle
control
RNA negative
control
218-bp dsRNA siRNA pool
0.64 mg/kg/
day
6.4 mg/kg/
day
64 mg/kg/
day
0.45 mg/kg/
day
4.9 mg/kg/
day
48 mg/kg/
day
Adrenal Glands: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Bone, Femur: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Bone, Humerus: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Brain, Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Colon: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Duodenum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Heart: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Ileum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 7/8 8/8
Ileum: Discoloration 0/8 0/8 0/8 0/8 0/8 0/8 1/8 0/8
Jejunum: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Kidneys: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Liver: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Lung: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Lymph Node, Mesenteric:
Normal
8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Muscle, Gastrocnemius:
Normal
8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Ovaries: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Pancreas: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Cervical: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Lumbar: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spinal Cord, Thoracic: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Spleen: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Stomach: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Thymus: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Urinary Bladder: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
Uterus: Normal 8/8 8/8 8/8 8/8 8/8 8/8 8/8 8/8
1 The range of calculated margins of exposure based on the highest doses tested in
this study was 4.6 107–3.4  108, utilizing mean construct-derived dsRNA expression
levels in ﬁeld trials with an insect protected corn grain (currently under development
and based uponWHO/GEMS acute 97.5th percentile food consumption values formaize
ﬂour, popcorn, and sweet corn in the general population and children 66 years old.
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tity to the target gene appear to have the most potential for gene
suppression upon reaching a target cell and sequences with less
than perfect sequence complementarity tend to have orders of
magnitude less potency in vitro than that observed with
sequences having full complementarity (Vaishnaw et al., 2010).
This consideration has been employed in designing the studies
presented herein, as a reasonable worst case scenario has been
utilized, exposure to sequences with 100% identity to the con-
suming organism. Furthermore, as discussed above, there is a
low potential for biologically meaningful uptake of ingested small
RNAs (Dickinson et al., 2013; Snow et al., 2013; Witwer et al.,
2013) and any RNA that undergoes uptake from the intestinal
tract is likely to undergo rapid elimination from the circulation
as observed with intravenous injection studies (Christensen
et al., 2013). Utilization of test sequences with perfect comple-
mentarity to the exposed organism as presented herein, demon-
strates that the use of bioinformatics to identify putative
hazards from ingestion of sequences with 100% identity to an
exposed mammal appear to be of little predictive value in hazard
characterization or risk assessment of ingested RNAs from agri-
cultural applications of RNA interference.
Gene expression changes are not sufﬁcient for producing a
physiological effect. Expression of a target protein must also be
modulated and such modulation must occur at a level sufﬁcient
for exhibiting a downstream physiological impact (e.g., hazard).
The collective impact of any gene expression changes that have
biological relevance is assessed not by evaluating potential for
gene modulation, but by evaluating any potential for phenotypic
impact on the test organism, as assessed through traditional
in vivo toxicity assessment. As noted by Vaishnaw and colleagues,
unformulated therapeutic siRNAs have been generally well toler-
ated in preclinical safety studies at doses >100 mg/kg by intrave-
nous administration (Vaishnaw et al., 2010), thus indicating that
potential changes in transcriptional proﬁles (e.g., target or off-tar-
get gene suppression) does not appear to impact safety in vivo.These results are also corroborated by Thompson and colleagues
who safely administered to rats doses of up to 200 mg/kg (intrave-
nously) of a stabilized RNA targeting rat p53 (Thompson et al.,
2012). The present study results utilizing a route of exposure more
relevant to agricultural biotechnology applications of RNAi demon-
strate the lack of toxicity and lack of target gene expression
impacts following oral exposure to siRNAs or a longer dsRNA.
These ﬁndings appear consistent with the weight of the scientiﬁc
evidence suggesting: (1) limited absorption of ingested RNAs; (2)
rapid clearance of RNA from the blood stream; and (3) the limited
potential for ingested RNA to reach a target cell in sufﬁcient quan-
tity to mediate RNAi. These data demonstrate the limited capacity
for ingested RNAs to mediate either on-target or off-target gene
regulation after administration of a sequence with 100% comple-
mentarity to the consuming organism.
Daily oral gavage administration to mice of either a pool of
four 21-mer small interfering RNAs (siRNAs) matching mouse
vATPase at dose levels of 0.45, 4.9, and 48 mg/kg or a 218-base
pair dsRNA matching mouse vATPase at dose levels of 0.64, 6.4,
and 64 mg/kg for 28 consecutive days did not produce any
adverse effects. The no observable adverse effect levels (NOAELs)
for the pool of 21-mer siRNAs or the 218-base pair dsRNA target-
ing mouse vATPase were therefore considered to be the highest
doses tested, 48 mg/kg and 64 mg/kg, respectively. In addition,
these test materials did not produce treatment-related suppres-
sion of local or systemic vATPase target gene expression. The high
doses utilized in this evaluation are estimated to be in excess of
1,000,000 fold higher than potential dietary exposures from bio-
technology-derived crop products currently under development.1
These data support the conclusion that biological barriers limit)
Table 14
Histopathology Evaluation of Male Mice.
Tissue: Findings out of Total Examined Vehicle control RNA negative control 218-bp dsRNA siRNA pool
64 mg/kg/day 45 mg/kg/day
Adrenal Glands
Normal 7/8 7/8 7/8 8/8
Accessory Adrenal 1/8 (1) – 1/8 (1) –
Hyperplasia, Subcapsular Spindle Cells 1/8 (1) 2/8 (1) 1/8 (1) –
Bone Marrow
Normal 0/0 0/0 0/1 0/0
Hyperplasia – – 1/1 (2) –
Bone, Femur
Normal 8/8 8/8 8/8 8/8
Brain
Normal 8/8 8/8 8/8 8/8
Colon
Normal 7/7 8/8 8/8 8/8
Tissue Missing 1/8 – – –
Duodenum
Normal 8/8 8/8 8/8 8/8
Heart
Normal 8/8 8/8 8/8 8/8
Ileum
Normal 8/8 8/8 8/8 8/8
Jejunum
Normal 8/8 8/8 8/8 8/8
Kidney
Normal 6/8 7/8 8/8 8/8
Basophilia, Tubular 1/8 (1) – – –
Inﬁltrate, Lymphocytic – 1/8 (1) – –
Mineralization 1/8 (1) – – –
Liver
Normal 8/8 5/8 7/8 5/8
Pigmentation – – – 1/8 (1)
Microgranuloma – 3/8 (1) 1/8 (1) 3/8 (1)
Necrosis, Individual Cell – 1/8 (1) – –
Lung
Normal 8/8 8/8 5/8 7/8
Hemorrhage – – 1/8 (1) 1/8 (1)
Inﬂammation – – 1/8 (1) –
Macrophages, Alveolar – – 1/8 (2) –
Lymph Node, Mesenteric
Normal 8/8 8/8 8/8 8/8
Muscle, Gastrocnemius
Normal 8/8 8/8 8/8 8/8
Pancreas
Normal 8/8 8/8 8/8 8/8
Spinal Cord, Cervical
Normal 8/8 8/8 8/8 8/8
Spinal Cord, Lumbar
Normal 8/8 8/8 8/8 8/8
Spinal Cord, Thoracic
Normal 8/8 8/8 8/8 8/8
Spleen
Normal 8/8 7/8 8/8 8/8
Hematopoiesis, Extramedullary – 1/8 (1) – –
Stomach
Normal 8/8 8/8 7/8 6/8
Dilatation – – 1/8 (1) 2/8 (1)
Testis
Normal 8/8 7/8 8/8 8/8
Atrophy – 1/8 (2) – –
Thymus
Normal 8/8 7/8 7/8 8/8
Congestion – 1/8 (1) – –
Involution – – 1/8 (2) –
Urinary Bladder
Normal 8/8 8/8 8/8 6/6
Tissue Missing – – – 2/8
Note: (), average severity rating of animals with lesion: 1 (minimal) to 5 (severe); –, no incidence.
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impact gene expression in the consuming organism. These
results therefore corroborate the established safety of ingestedRNA and call into question the necessity for toxicological studies
with puriﬁed RNA in establishing the food and feed safety of
biotechnology-derived crops expressing transgenic dsRNAs.
Table 15
Histopathology evaluation of female mice.
Tissue: Findings out of Total Examined Vehicle control RNA negative control 218-bp dsRNA siRNA pool
64 mg/kg/day 45 mg/kg/day
Adrenal Glands
Normal 6/8 2/8 5/8 3/8
Accessory Adrenal – – – 1/8 (1)
Hyperplasia, Subcapsular Spindle Cells 2/8 (1) 6/8 (1) 3/8 (1) 5/8 (1)
Bone Marrow
Normal 0/0 0/0 0/0 0/0
Bone, Femur
Normal 8/8 7/7 8/8 8/8
Tissue Missing – 1/8 – –
Brain
Normal 8/8 8/8 8/8 8/8
Colon
Normal 8/8 8/8 8/8 8/8
Duodenum
Normal 8/8 8/8 8/8 8/8
Heart
Normal 8/8 8/8 8/8 8/8
Ileum
Normal 8/8 8/8 8/8 8/8
Jejunum
Normal 8/8 8/8 8/8 7/7
Tissue Missing – – – 1//8
Kidney
Normal 4/8 6/8 7/8 7/8
Basophilia, Tubular 1/8 (1) – – 1/8 (1)
Cast, Tubular 1/8 (1) – 1/8 (1) –
Fibrosis 1/8 (1) – – –
Hyperplasia 1/8 (1) – – –
Inﬁltrate, Lymphocytic 2/8 (1.5) 1/8 (1) – –
Mineralization – 1/8 (1) – –
Liver
Normal 8/8 5/8 7/8 6/8
Microgranuloma – 3/8 (1) 1/8 (1) 2/8 (1)
Necrosis, Individual Cell – 1/8 (1) – –
Lung
Normal 8/8 8/8 8/8 8/8
Lymph Node, Mesenteric
Normal 8/8 7/7 7/7 8/8
Tissue Missing – 1/8 1/8 –
Muscle, Gastrocnemius
Normal 8/8 7/7 7/8 8/8
Tissue Missing – 1/8 – –
Regeneration – – 1/8 (1) –
Ovaries
Normal 8/8 7/8 7/8 8/8
Cyst – 1/8 (2) 1/8 (1) –
Pancreas
Normal 8/8 8/8 8/8 8/8
Spinal Cord
Cyst, Epidermal Inclusion 0/0 0/0 1/1 (1) 0/0
Spinal Cord, Cervical
Normal 8/8 7/7 8/8 8/8
Tissue Missing – 1/8 – –
Spinal Cord, Lumbar
Normal 8/8 7/7 8/8 8/8
Tissue Missing – 1/8 – –
Spinal Cord, Thoracic
Normal 8/8 7/7 8/8 8/8
Tissue Missing – 1/8 – –
Spleen
Normal 8/8 8/8 8/8 8/8
Stomach
Normal 7/8 6/8 7/8 7/8
Dilatation 1/8 (1) 2/8 (1) 1/8 (1) –
Inﬂammation, Acute – – – 1/8 (1)
Thymus
Normal 8/8 8/8 8/8 7/7
Tissue Missing – – – 1/8
Urinary Bladder
Normal 8/8 8/8 7/8 8/8
Inﬁltrate, Lymphocytic – – 1/8 (1) –
Uterus
Normal 8/8 8/8 8/8 8/8
Note: (), average severity rating of animals with lesion: 1 (minimal) to 5 (severe); –, no incidence.
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Fig. 2. vATPase Expression in Mice. Animals were treated with indicated doses of vATPase-targeting dsRNA or siRNA relative to control untreated mice in: (A) stomach, (B)
duodenum, (C) ileum, (D) liver, (E) kidney, (F) brain, and (G) humerus. Data represent mean expression values relative to control (±SD) and statistical signiﬁcance is indicated
at p < 0.05 (⁄) or p < 0.01 (⁄⁄).
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